Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells; Correlation established between EO2463-ind ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." Normally, a B cell ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Weill Cornell Medicine scientists have identified Hodgkin lymphoma cells as immune cells halted midway between B cells and plasma cells, reframing the disease as one of failed development. The ...

Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This ...

Urban China is expected to lead globally in diagnosed PCNSL cases in 2024 and 2029. Current treatment relies on off-label use and BTK inhibitors, but there's a significant unmet need driving ...